PTPA and B-cell chronic lymphocytic leukemia: Notably, for PP2A activation, we used the highly specific activator DT-061, that also reduces leukemic burden in peripheral blood, spleen and bone marrow in the Eμ-TCL1 adoptive transfer model of CLL, with a concomitant decrease in N1-ICD expression.